162 related articles for article (PubMed ID: 34265044)
1. Effects of Renin-Angiotensin-Aldosterone Inhibitors on Early Outcomes of Hypertensive COVID-19 Patients: A Randomized Triple-Blind Clinical Trial.
Najmeddin F; Solhjoo M; Ashraf H; Salehi M; Rasooli F; Ghoghaei M; Soleimani A; Bahreini M
Am J Hypertens; 2021 Nov; 34(11):1217-1226. PubMed ID: 34265044
[TBL] [Abstract][Full Text] [Related]
2. A Retrospective Study from 2 Centers in China on the Effects of Continued Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Patients with Hypertension and COVID-19.
Wang Z; Zhang D; Wang S; Jin Y; Huan J; Wu Y; Xia C; Li Z; Qi X; Zhang D; Han X; Zhu X; Qu Y; Wang Q
Med Sci Monit; 2020 Sep; 26():e926651. PubMed ID: 32969367
[TBL] [Abstract][Full Text] [Related]
3. Impact of renin-angiotensin-aldosterone system inhibition on mortality in critically ill COVID-19 patients with pre-existing hypertension: a prospective cohort study.
Sato K; White N; Fanning JP; Obonyo N; Yamashita MH; Appadurai V; Ciullo A; May M; Worku ET; Helms L; Ohshimo S; Juzar DA; Suen JY; Bassi GL; Fraser JF; Arora RC;
BMC Cardiovasc Disord; 2022 Mar; 22(1):123. PubMed ID: 35321649
[TBL] [Abstract][Full Text] [Related]
4. Association Between Renin-Angiotensin-Aldosterone System Inhibitors and Clinical Outcomes in Patients With COVID-19: A Systematic Review and Meta-analysis.
Baral R; Tsampasian V; Debski M; Moran B; Garg P; Clark A; Vassiliou VS
JAMA Netw Open; 2021 Mar; 4(3):e213594. PubMed ID: 33787911
[TBL] [Abstract][Full Text] [Related]
5. Management of Renin-Angiotensin-Aldosterone System blockade in patients admitted to hospital with confirmed coronavirus disease (COVID-19) infection (The McGill RAAS-COVID- 19): A structured summary of a study protocol for a randomized controlled trial.
Aflaki M; Flannery A; Ferreira JP; Cheng MP; Kronfli N; Marelli A; Zannad F; Brophy J; Afillalo J; Huynh T; Giannetti N; Bessissow A; Ezekowitz JA; Lopes RD; Ambrosy AP; Craig M; Sharma A
Trials; 2021 Feb; 22(1):115. PubMed ID: 33546734
[TBL] [Abstract][Full Text] [Related]
6. Effect of continuing the use of renin-angiotensin system inhibitors on mortality in patients hospitalized for coronavirus disease 2019: a systematic review, meta-analysis, and meta-regression analysis.
Liu Q; Fu W; Zhu CJ; Ding ZH; Dong BB; Sun BQ; Chen RC
BMC Infect Dis; 2023 Jan; 23(1):53. PubMed ID: 36694122
[TBL] [Abstract][Full Text] [Related]
7. Blood Pressure Control Following Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers: Insights from a Triple-Blind, Randomized, Clinical Trial.
Sharifan A; Bahreini M; Ashraf H; Najmeddin F
J Clin Pharmacol; 2023 Nov; 63(11):1205-1209. PubMed ID: 37341147
[TBL] [Abstract][Full Text] [Related]
8. Impact of the withdrawal of renin-angiotensin-aldosterone inhibitors on mortality in COVID-19 patients.
Caro-Codón J; Rey JR; Iniesta AM; Rosillo SO; Castrejon-Castrejon S; Rodriguez-Sotelo L; Garcia-Veas JM; Marco I; Martinez LA; Martin-Polo L; Merino C; Martinez-Cossiani M; Buño A; Gonzalez-Valle L; Herrero A; López-de-Sá E; Merino JL;
Rev Port Cardiol; 2022 Oct; 41(10):823-830. PubMed ID: 35784098
[TBL] [Abstract][Full Text] [Related]
9. The use of renin-angiotensin-aldosterone system (RAAS) inhibitors is associated with a lower risk of mortality in hypertensive COVID-19 patients: A systematic review and meta-analysis.
Wang Y; Chen B; Li Y; Zhang L; Wang Y; Yang S; Xiao X; Qin Q
J Med Virol; 2021 Mar; 93(3):1370-1377. PubMed ID: 33095513
[TBL] [Abstract][Full Text] [Related]
10. Effects of Renin-Angiotensin System Inhibitors on Mortality and Disease Severity of COVID-19 Patients: A Meta-analysis of Randomized Controlled Trials.
Yin J; Wang C; Song X; Li X; Miao M
Am J Hypertens; 2022 May; 35(5):462-469. PubMed ID: 35512430
[TBL] [Abstract][Full Text] [Related]
11. Chronic use of renin-angiotensin-aldosterone inhibitors in hypertensive COVID-19 patients: Results from a Spanish registry and meta-analysis.
Aparisi Á; Catalá P; Amat-Santos IJ; Marcos-Mangas M; López-Otero D; Veras C; López-Pais J; Cabezón-Villalba G; Cacho Antonio CE; Candela J; Antúnez-Muiños P; Gil JF; González Ferrero T; Rojas G; Pérez-Poza M; Uribarri A; Otero-García O; García-Granja PE; Jiménez Ramos V; Revilla A; Dueñas C; Gómez I; González-Juanatey JR; San Román JA
Med Clin (Barc); 2022 Apr; 158(7):315-323. PubMed ID: 34088524
[TBL] [Abstract][Full Text] [Related]
12. Angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARBs) may be safe for COVID-19 patients.
Wang W; Zhao X; Wei W; Fan W; Gao K; He S; Zhuang X
BMC Infect Dis; 2021 Jan; 21(1):114. PubMed ID: 33494713
[TBL] [Abstract][Full Text] [Related]
13. Effects of Angiotensin Receptor Blockers (ARBs) on In-Hospital Outcomes of Patients With Hypertension and Confirmed or Clinically Suspected COVID-19.
Soleimani A; Kazemian S; Karbalai Saleh S; Aminorroaya A; Shajari Z; Hadadi A; Talebpour M; Sadeghian H; Payandemehr P; Sotoodehnia M; Bahreini M; Najmeddin F; Heidarzadeh A; Zivari E; Ashraf H
Am J Hypertens; 2020 Dec; 33(12):1102-1111. PubMed ID: 32920644
[TBL] [Abstract][Full Text] [Related]
14. Impact of renin-angiotensin-aldosterone-system inhibitor drugs on mortality in patients with atrial fibrillation and hypertension.
Xu W; Yang YM; Zhu J; Wu S; Wang J; Zhang H; Shao XH
BMC Cardiovasc Disord; 2022 Apr; 22(1):141. PubMed ID: 35365067
[TBL] [Abstract][Full Text] [Related]
15. Associastion of In-hospital Use of Statins, Aspirin, and Renin-Angiotensin-Aldosterone Inhibitors with Mortality and ICU Admission Due to COVID-19.
Vahedian-Azimi A; Rahimibashar F; Najafi A; Kidde J; Shahriary A; Shojaei S; Pourhoseingholi MA; Jamialahmadi T; Sahebkar A
Adv Exp Med Biol; 2021; 1327():205-214. PubMed ID: 34279841
[TBL] [Abstract][Full Text] [Related]
16. Impact of Treatment with Renin-Angiotensin System Inhibitors on Clinical Outcomes in Hypertensive Patients Hospitalized with COVID-19.
Negreira-Caamaño M; Piqueras-Flores J; Martínez-DelRio J; Nieto-Sandoval-Martin-DeLaSierra P; Aguila-Gordo D; Mateo-Gomez C; Salas-Bravo D; Rodriguez-Martinez M; Negreira-Caamaño M
High Blood Press Cardiovasc Prev; 2020 Dec; 27(6):561-568. PubMed ID: 32949380
[TBL] [Abstract][Full Text] [Related]
17. Differential Effects of Combination of Renin-Angiotensin-Aldosterone System Inhibitors on Central Aortic Blood Pressure: A Cross-Sectional Observational Study in Hypertensive Outpatients.
Pradhan A; Vishwakarma P; Bhandari M; Sethi R; Narain VS
Cardiovasc Ther; 2020; 2020():4349612. PubMed ID: 32983258
[TBL] [Abstract][Full Text] [Related]
18. The effect of continuing versus withholding angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers on mortality and major adverse cardiovascular events in hypertensive patients undergoing elective non-cardiac surgery: study protocol for a multi-centric open-label randomised controlled trial.
Misra S; Parida S; Sahajanandan R; Behera BK; Senthilnathan M; Mariappan R; Chandy TT;
Trials; 2022 Aug; 23(1):670. PubMed ID: 35978368
[TBL] [Abstract][Full Text] [Related]
19. Risk of Covid-19-Related Hospitalization and More Severe Outcomes in Medicare Beneficiaries Treated with Renin-Angiotensin-Aldosterone System Inhibitors for Hypertension.
Graham DJ; Izurieta HS; Muthuri SG; Zhang D; Sandhu AT; Lu Y; Zhao Y; Feng Y; Eworuke E; Lyu H; Gandotra C; Smith ER; Avagyan A; Wernecke M; Kelman JA; Forshee RA; MaCurdy TE
J Gen Intern Med; 2021 Dec; 36(12):3802-3809. PubMed ID: 34599472
[TBL] [Abstract][Full Text] [Related]
20. Use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in context of COVID-19 outbreak: a retrospective analysis.
Xu J; Huang C; Fan G; Liu Z; Shang L; Zhou F; Wang Y; Yu J; Yang L; Xie K; Huang Z; Huang L; Gu X; Li H; Zhang Y; Wang Y; Hayden FG; Horby PW; Cao B; Wang C
Front Med; 2020 Oct; 14(5):601-612. PubMed ID: 32621202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
